Deep oncology expertise at every level for your study

OCT Oncology ™ is a dedicated solutions package aimed at helping pharma from early to late stage oncology treatment development. OCT Clinical is a full-service oncology CRO with a professional network of 300 leading oncology clinics in 10 countries, led by a highly-skilled clinical team. This year, we carried out our 80th oncology study and have recruited 35,466 patients.

Submit an RFP

Why you should go with OCT Oncology™

45 different indications, including Carcinoma, Leukemia, Lymphoma, Myeloma and Sarcoma
Access to the right patients: 35,466 patients in 80 oncology studies
Exclusive partnerships with 300 leading oncology clinics in 10 countries
We stick to our word: 76% of studies are completed on time and on budget
Transparent pricing: our budgets consist of more than 400 cost items, which makes budget planning more accurate and efficient
A dedicated and well trained project team including Oncology medical experts and experienced CRAs
Seamless communication: upfront and efficient communication prevents lagging due to mismanagement and ensures that sponsors have a cooperative experience

Support from start to finish at every stage of your study

1. Free feasibility report
2. Start up
3. Study conduct
4. Data analysis
5. Regulatory submissions
6. Post submission
7. Study success

17 years of Oncology expertise

We provide a full range of high-quality clinical trial services for Phase I-IV and BE studies. We offer both full-service clinical study engagements and stand alone services in a number of therapeutic areas.

By cancer type

Experience by phase

Special expertise in Immuno-oncology studies

Succeeding in target treatment development dictates the use of innovative methods to quickly identify and deliver the right therapy to the right patient. Within our vast portfolio of oncology studies, we are proud to offer adequate expertise in immuno-oncology studies. Look at the snapshot with our most prominent cases in this area.

Submit an RFP
Studies
Phase
Year
Patients*
Status
NSCLC
III
2019
360
Ongoing
Solid Tumor/ NSCLC (with high PD-L1 expression) (Anti PD-L1 antibody)
I
2018
104
Ongoing
Non-Hodgkin’s Lymphoma (Anti CD-20)
II
2017
50
Complete
Chronic Lymphocytic Leukemia (Anti-CD20 mAB + PI3K kinase inhibitor)
III
2016
30
Ongoing
B-cell Lymphoma (Rituximab)
II
2016
104
Ongoing
Non-small cell lung and Epithelial ovarian cancer (PD-L1 inhibitor)
I
2013
60
Complete
Solid Tumors (PD-L1 inhibitor)
I
2013
40
Complete
Locally Advanced Pancreatic Cancer (Onco-vaccine)
II
2011
40
Complete

* Number of patients recruited by OCT Clinical

On average 1.5 x faster enrollment rate compared to other regions

Ph3 Breast Cancer
Ukraine
1.4 p/s/m
USA
0.5 p/s/m
Latvia
0.5 p/s/m
Ph3 Ovarian Cancer
Russia
1.01 p/s/m
Sweden
0.5 p/s/m
Germany
0.5 p/s/m
Ph3 Non-small Lung Cancer
Latvia
2.01 p/s/m
South Korea
0.4 p/s/m
Germany
0.5 p/s/m

* patients / site / month

Our clients

We never settle for a compromise when choosing between quality, timeline and budget. We always deliver the best on all three.

Gatis Klaucans
Director of Clinical Operations, OCT Latvia

See the stories of the clients who chose OCT Oncology™

OCT Clinical is privileged to support global pharmaceutical companies and biotechs, and with this experience we can help you follow the right steps towards faster treatment approvals, so medicines can reach patients more rapidly.

Relationships are important to us

Reach out to us to learn more about how our approach, experience, investigator relationships, bid transparency and flexibility deliver success for our clients.

Let’s start a new study together

Submit an RFP

Thank you for your request!
Our team will respond to you within 24 hours.